NGR012: A Phase II Study of NGR-hTNF Administered in Combination With Doxorubicin Every 3 Weeks in Patients Affected by Advanced or Metastatic Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2018
At a glance
- Drugs NGR-TNF (Primary) ; Doxorubicin
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- Acronyms NGR012
- Sponsors MolMed
- 31 Aug 2018 Biomarkers information updated
- 03 Jun 2013 Data were presented at the 49th ASCO annual meeting, according to a MolMed media release.
- 04 Jun 2012 Three-year follow-up data were presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a MolMed media release.